Approval timelines for clinical trials in India have slipped back to the pre-pandemic days, industry insiders feel. During the pandemic, trial approval timelines had significantly improved by 30-40 per cent, they claim.
Speaking to Business Standard, Sanjay Vyas, Global SBU Head-Clinical Logistics and Global Safety Services, and Managing Director-India at Parexel, one of the largest clinical research organizations (CROS) in the world, says that in the last 12 months, around 110 clinical trial applications have been approved by the Indian regulator. Parexel is working on 30 clinical trials in India at the moment out of the 600-odd trials it is conducting worldwide. This is despite the fact that the CRO employs more than 6,000 people in India, or about 20 per cent of its global workforce.
Vyas says application timelines had seen a significant boost during the pandemic when real-time monitoring and a more decentralised approach was taken, including remote monitoring. Approvals for trials could then come in as fast as 30 days or so for Covid-19 studies and around 45 days for nonCovid-19 subjects.
Sanish Davis, President, Indian Society for Clinical Research (ISCR), agrees: "Regulatory timelines in India are long up to 90 working days, or 4.5 calendar months. On top of this, there are ethics committee approval timelines too, which in India is around two-three months as against the global average of one-two months."
ãã®èšäºã¯ Business Standard ã® June 18, 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã ?  ãµã€ã³ã€ã³
ãã®èšäºã¯ Business Standard ã® June 18, 2024 çã«æ²èŒãããŠããŸãã
7 æ¥éã® Magzter GOLD ç¡æãã©ã€ã¢ã«ãéå§ããŠãäœåãã®å³éžããããã¬ãã¢ã ã¹ããŒãªãŒã9,000 以äžã®éèªãæ°èã«ã¢ã¯ã»ã¹ããŠãã ããã
ãã§ã«è³Œèªè ã§ã? ãµã€ã³ã€ã³
Keep gods out of politics: SC
Says no proof yet, slams CM Naidu
Women & child care get booster shot as hospitals eye growth
Sensing high demand for specialised women and child health care services, hospitals are ramping up new centres, expanding workforce and bringing more super-specialities into their fold.
THE NECESSARY AND THE BEAUTIFUL
Emami has built itself through acquisitions. But there is more coming, with a startup turn
Make in India @ 10: A vision for global manufacturing leadership
On this momentous occasion of 10 years of the Make in India, it's time to reflect on the transformational journey India has undertaken towards the mission of making itself a global manufacturing hub.
Rajasthan signs â¹12.5 trn MoUs ahead of investment meet
Investment agreements (MoUs) worth â¹12.5 trillion have been signed during Mumbai and Delhi roadshows in the run-up to the \"Rising Rajasthan\" global investment summit to be held in Jaipur from December 9-11, Rajasthan Chief Minister Bhajan Lal Sharma said on Monday.
SURRENDER VALUE NORMS KICK IN TODAY Life insurers begin rolling out revised bestsellers
With the new surrender value norms effective from Tuesday, most life insurance companies are immediately rolling out revised versions of their bestselling, non-participating products.
Traders must classify imports of lab chemicals under appropriate heads
We refer to Para 5.15(c) of HBP 2023, which was amended by the recent Public Notice no.15 dated 25th July 2024. Will this amendment apply to EPCG authorisations issued in the previous policy periods also?
Chinese stocks enter bull mkt with biggest surge since 2008
Chinese stocks extended one of their most remarkable turnarounds in history, soaring for a ninth straight day as government stimulus entices investors back to one of the most beaten-down markets worldwide.
Sebi may maintain status quo on largecap stock pool expansion
20% smallcap and midcap investment leeway to keep largecap expansion in abeyance
Afcons Infra likely to opt for â¹4,000 cr pre-IPO placement
Afcons Infrastructure, part of Shapoorji Pallonji (SP) Group, plans to conduct a pre-listing sale of â¹4,000 crore, according to sources.